dr. sartor on outcomes with 177lu-psma-617 after radium-223 in mcrpc
Published 4 years ago • 394 plays • Length 1:38Download video MP4
Download video MP3
Similar videos
-
1:24
dr. sartor on mechanism of action and safety of radium-223 in mcrpc
-
1:50
dr. gafita on sequencing 177lu-psma-617 in mcrpc
-
4:48
vision: lu-177-psma-617 in mcrpc
-
0:55
dr. sartor on patients in the alsympca radium-223 trial
-
1:25
dr. sartor discusses the novel agent radium-223
-
11:49
lutetium-177 (pluvicto) vs. psma-actinium | #markscholzmd #alexscholz #pcri
-
7:52
does high psa levels = prostate cancer? | dr steven tucker
-
2:16
how does a prostate-specific antigen (psa) test work?
-
1:08
dr. sartor on provenge in combination with radium-223
-
1:08
dr. a. oliver sartor on the mechanism of action of radium-223
-
2:25
sartor: expanded access program for radium-223 (xofigo)
-
1:00
oliver sartor, md, regarding recent outcomes investigating 225ac-psma-617 in patients with apc
-
1:20
dr. sartor on provenge in combination with radium-223
-
1:04
dr. oliver sartor discusses radium-223 in early prostate cancer
-
1:41
dr. oliver sartor on doubling the dosage of radium-223 in patients with crpc
-
0:53
dr. sartor on impact of radium-223 for community oncologists
-
0:47
dr. oliver sartor discusses a new prostate cancer trial combining radium-223 and provenge
-
1:05
oliver sartor discusses common questions about radium-223
-
2:13
dr. sartor on emerging agents in prostate cancer
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
0:42
oliver sartor discusses clinical use of radium-223
-
3:01
preliminary findings in mcrpc for fractionated dose 177lu-psma-617